Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | PNMT | P11086 | 6/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808272 | 1.00 | ASIC3 (0.60) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL1000239 | 0.98 | ASIC3 (0.59) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL329770 | 0.93 | ASIC3 (0.69) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL1000104 | 0.91 | ASIC3 (0.68) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL11325344 | 0.89 | ASIC3 (0.50) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL23727496 | 0.89 | HTR2C (0.58) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL2675790 | 0.86 | ASIC3 (0.67) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL19443102 | 0.86 | PNMT (0.51) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL13717588 | 0.85 | ASIC3 (0.65) | ASIC3HTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL31021978 | 0.85 | ASIC3 (0.65) | ASIC3HTR2AHTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457245-B | Synthesis method of 7- (trifluoromethyl) isoquinoline-5-amine | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-112457245-A | Synthesis method of 7- (trifluoromethyl) isoquinoline-5-amine | 苏州康润医药有限公司 | 2021-03-09 | — | — | CN | claimed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| WO-2025079045-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025049767-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| WO-2024005526-A1 | NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 동국대학교 산학협력단 | 2024-01-04 | — | — | WO | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| EP-4100005-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
| EP-3686198-B1 | MU-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2022-12-14 | — | — | EP | disclosed |
| CN-115403570-A | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-1144405-A1 | TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042036-A1 | TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| US-6046210-A | ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-04 | — | — | US | disclosed |
| CN-1224418-A | Tetrahydroisoquinoline derivs. as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM PLC (GB) | 1999-07-28 | — | — | CN | disclosed |
| EP-0917530-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-26 | — | — | EP | disclosed |
| WO-1997043262-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-11-20 | — | — | WO | disclosed |
| US-4062961-A | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES | SMITHKLINE CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
| US-3988339-A | 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE | SMITHKLINE CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | ASIC3 1006/4885HTR2A 4619/4885HTR2C 4642/4885 |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | ASIC3 4146/4885HTR2A 4492/4885HTR2C 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.